Intensity Therapeutics Inc (INTS)

Mar 13, 2025, 4:07 PM EDT - 5 weeks ago

Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

Jan 28, 2025, 8:00 AM EST - 3 months ago

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review

Jan 10, 2025, 8:00 AM EST - 3 months ago

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

Dec 12, 2024, 8:00 AM EST - 4 months ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Nov 21, 2024, 8:00 AM EST - 5 months ago

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

Nov 18, 2024, 8:00 AM EST - 5 months ago

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)

Nov 13, 2024, 4:06 PM EST - 5 months ago

Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 8, 2024, 8:01 AM EST - 5 months ago

Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting

Oct 31, 2024, 9:00 AM EDT - 6 months ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)

Sep 4, 2024, 8:00 AM EDT - 8 months ago

Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 4:19 PM EDT - 9 months ago

Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 9, 2024, 8:01 AM EDT - 10 months ago

Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma

May 15, 2024, 8:01 AM EDT - 1 year ago

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors

May 14, 2024, 9:38 AM EDT - 1 year ago

Intensity Therapeutics: A Bargain For A Late-Stage Company With A Remarkable Oncology Drug

May 10, 2024, 8:01 AM EDT - 1 year ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate

May 9, 2024, 4:08 PM EDT - 1 year ago

Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 2, 2024, 8:01 AM EDT - 1 year ago

Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024

Mar 14, 2024, 4:09 PM EDT - 1 year ago

Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 14, 2024, 8:00 AM EDT - 1 year ago

Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024

Feb 21, 2024, 8:01 AM EST - 1 year ago

Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference

Jan 3, 2024, 8:01 AM EST - 1 year ago

Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program

Dec 12, 2023, 8:01 AM EST - 1 year ago

Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer

Dec 8, 2023, 8:30 AM EST - 1 year ago

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS

Dec 1, 2023, 8:01 AM EST - 1 year ago

Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium

Nov 13, 2023, 8:01 AM EST - 1 year ago

Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update

Nov 2, 2023, 7:01 AM EDT - 1 year ago

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023

Sep 7, 2023, 8:01 AM EDT - 1 year ago

Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma

Sep 5, 2023, 8:01 AM EDT - 1 year ago

Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 14, 2023, 7:01 AM EDT - 1 year ago

Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update

Aug 7, 2023, 7:01 AM EDT - 1 year ago

Intensity Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update

Jul 10, 2023, 8:00 AM EDT - 1 year ago

Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds

Jul 5, 2023, 4:15 PM EDT - 1 year ago

Intensity Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds

Jul 1, 2023, 3:15 AM EDT - 1 year ago

U.S. IPO Weekly Recap: Sizable Deals Close Out The Q2 IPO Market, Led By Thrift Store Savers

AENT FIHL GENK KGS SRFM SVV VTMX

Jun 29, 2023, 8:00 PM EDT - 1 year ago

Intensity Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds

Jun 6, 2023, 7:35 AM EDT - 2 years ago

Intensity Therapeutics Reports INT230-6 Can Cause Immune Priming in Historically Quiescent Breast Cancers

Jun 3, 2023, 8:00 AM EDT - 2 years ago

Intensity Therapeutics' INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas

Dec 8, 2022, 7:01 AM EST - 2 years ago

Intensity Therapeutics' Reports Up to 100% Tumor Necrosis After One Dose of Lead Asset, INT230-6 in Phase 2 INVINCIBLE Neoadjuvant Breast Cancer Study at the San Antonio Breast Cancer Symposium (SABCS)

Nov 18, 2022, 7:01 AM EST - 2 years ago

Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTO

Nov 11, 2022, 7:01 AM EST - 2 years ago

Intensity Therapeutics' INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Pembrolizumab in Patients with Relapsed, Refractory, Metastatic Solid Tumor Cancers

Nov 10, 2022, 7:01 AM EST - 2 years ago

Intensity Therapeutics, The Ottawa Hospital and Ontario Institute for Cancer Research Report INT230-6 Demonstrates Tumor Necrosis and Immune Activation in Early Stage Breast Cancers

Sep 22, 2022, 9:30 AM EDT - 2 years ago

Intensity Therapeutics Finalizes Terms For $10 Million IPO